Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Conditions

Breast Neoplasms 1888Carcinoma, Non-Small-Cell Lung 1348Prostatic Neoplasms 980Colorectal Neoplasms 851Multiple Myeloma 741Leukemia, Myeloid, Acute 725Neoplasms 691Lung Neoplasms 679Neoplasm Metastasis 642Lymphoma 579Carcinoma, Hepatocellular 571Pancreatic Neoplasms 566Stomach Neoplasms 522Leukemia 511Recurrence 493Leukemia, Lymphocytic, Chronic, B-Cell 459Precursor Cell Lymphoblastic Leukemia-Lymphoma 452Melanoma 451Lymphoma, Non-Hodgkin 442Ovarian Neoplasms 426Lymphoma, Large B-Cell, Diffuse 423Squamous Cell Carcinoma of Head and Neck 416Myelodysplastic Syndromes 416Head and Neck Neoplasms 403Brain Neoplasms 403Rectal Neoplasms 397Glioblastoma 375Carcinoma, Renal Cell 350Hodgkin Disease 338Esophageal Neoplasms 337

Interventions

Metyrapone 2Osilodrostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × OTHER × Adrenal Hyperplasia, Congenital × Clear all
NCT07104812 2026-02-11

Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)

Mayo Clinic

Phase 2 Recruiting
15 enrolled

ACTH Syndrome, Ectopic, Adrenal Hyperplasia, Congenital, Cushing Syndrome

NCT06106295 2025-09-22

Metyrapone for Mild Autonomous Cortisol Secretion (MACS)

Mayo Clinic

Phase 2 Active not recruiting
30 enrolled

ACTH Syndrome, Ectopic, Adrenal Hyperplasia, Congenital, Cushing Syndrome

NCT07138274 2025-08-22

Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS

Mayo Clinic

Phase 2 Not yet recruiting
90 enrolled

ACTH Syndrome, Ectopic, Adrenal Hyperplasia, Congenital, Cushing Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡